Pharmaceutical companies are betting big on cancer immunotherapies that rely on the PD-1 protein and its ligands, PD-L1 and PD-L2, to initiate an immune response.
Two of the nation's biggest nonprofit health systems—Dignity Health and Catholic Health Initiatives—launched a precision medicine program that has the potential to create the largest collection of clinical cancer data ever compiled by a single organization.
The National Cancer Moonshot Initiative is not slated to receive funding in fiscal 2017—neither the House nor Senate appropriations bill includes the $680 million the White House proposed for Vice President Joe Biden's project.
Dan Sargent, one of the world's foremost experts in oncology clinical trials, died unexpectedly on Sept. 22. Sargent died from an acute illness, Mayo officials said. He was 46.
Research Project Grant funding at NCI has increased 25 percent, from $400 million in 2013 to $500 million in 2015, NCI Acting Director Douglas Lowy said to the National Cancer Advisory Board Sept. 7.
A brief consult with an undergraduate earning a B or above in Statistics 101 might have acquainted Spectrum Pharmaceuticals executives with all the science that would have saved them from a devastating encounter with an FDA advisory committee.
Vice President Joe Biden Sept. 16 announced a series of initiatives to improve the safety, accessibility, and impact of clinical research—one of the central goals of the National Cancer Moonshot Initiative.
NCI will urge increased and sustained appropriations for carrying out ten recommendations put forward by the Blue Ribbon Panel, the institute's scientific advisory panel to the National Cancer Moonshot Initiative.
The Blue Ribbon Panel—a group of experts selected to identify scientific opportunities for the National Cancer Moonshot Initiative—has submitted 10 recommendations to the National Cancer Advisory Board.
The Association of American Cancer Institutes and the White House Cancer Moonshot Task Force are developing a new method for funding research at academic cancer centers through private investment and philanthropy.
